{"prompt": "['OSTPDL1', 'Page 45 of 60', 'Timing: prior to start of therapy and prior to cycle 3. Samples should be', 'sent via FedEx overnight services to:', 'Paul G. Thomas, PhD', 'Integrated Research Center, Room E7054', \"St. Jude Children's Research Hospital\", '262 Danny Thomas Place', 'Memphis, TN 38105', 'On the day of sample acquisition, please contact Paul Thomas or Ben', 'Youngblood at (901)595-6749 to arrange for pickup of materials.', 'Samples will be stained with fluorescently labeled antibodies and sorted', 'for single cell analysis (1/3 of the sample) with the remaining sample', 'sorted on specific cell phenotypes for transcriptional and epigenetic', 'analysis.', 'Preparation of single cell suspension: Tumor sample (from freshly-', 'resected surgical specimen) is weighed and sequentially minced into', 'small pieces (approx. 3 mm in size) using scissors or scalpel. Tumor', 'tissue is digested at 37\u00b0C in RPMI medium supplemented with 5% FBS,', 'Collagenase 4, and DNase I. Digested tumors are homogenized by', 'pipetting, and filtered through a 70 um cell strainer. The remaining', 'undigested pieces are forced to pass through the strainer using a syringe', 'plunger. The single cell suspension is washed 3 times with ice cold PBS,', 'and RBC are lysed (if needed) using an ammonium chloride isotonic', 'solution. The number of live cells is determined using a hemocytometer', 'after exclusion of dead cells by Trypan blue dye.', 'Polyparametric immunophenotypic analysis: Cells are labeled with', 'fluorescent conjugated antibodies against the listed human epitopes, and', 'subsequently analyzed in a flow cytometer (BD LSRII). We will evaluate', 'PD-L1 expression in cell surface of infiltrating leukocytes (CD45 +', 'fraction) as well as in CD45 - fraction, which primary consists of tumor', 'cells.', 'Specificity', 'Fluorophore', 'Clone', 'CCR7', 'FITC', 'G043H7', 'PD1', 'PE', 'EH12.2H7', 'TIM3', 'PECY7', 'F38-2E2', 'CD45RO', 'APC', 'UCHL1', 'CD3', 'APCCY7', 'SK7', 'CD8a', 'PB (421)', 'RPA-T8', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 46 of 60', 'CD45', 'BV605', 'HI30', 'PDL1', 'BV786', 'MIH1', '(dead cell', '7AAD', 'n/a', 'exclusion', 'dye)', 'Samples sent to St. Jude', 'All', 'data associated with patient samples are protected by using a secure', 'database. All samples will be stored in liquid nitrogen. These freezers are', 'located at St. Jude in a secure facility. All specimens are stored in secure,', 'limited access facilities with sufficient security, back-up and emergency', 'support capability and monitoring to ensure long-term integrity of the', 'specimens for research. Specimens are stored in accordance will', 'applicable HHS and FDA Protection of Human Subjects Regulations in', 'accordance with SJCRH Federal-wide Assurance. The St. Jude IRB reviews', 'policies and procedures for labeling, data collection and storage, access,', 'and security. The IRB will review protection of privacy issues prior to', 'acceptance of any new work and in the event of change impacting privacy', 'issues in existing work.', 'It is the intent and purpose of the investigators at St. Jude to accept only de-', 'identified samples and sample information. To the best of our ability, every', 'effort will be made to ensure that protected information is not sent', 'electronically or by hard copy or on vial labels.', '9.0', 'EVALUATION CRITERIA', '9.1', 'Response Definitions and Criteria for Solid Tumors', 'See the table in section 7.1 for the schedule of tumor evaluations. In', 'addition to the scheduled scans, a confirmatory scan should be obtained', '28 days following initial documentation of objective response.', 'Response and progression will be evaluated in this study using the', 'revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline', '(version 1.1)90. Key points are that up to 5 target lesions may be', 'identified and that changes in the largest diameter (unidimensional', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}